PDPN and neoplasm: While these pathways may also contribute to neolymphatic outgrowth in tumors [61], the application of inhibitory strategies to block the relevant pathways/effectors (which include podoplanin, spleen tyrosine kinase (SYK)/SH2-domain containing leukocyte protein of 76 kDa (SLP-76), Rac1/Ras homology gene family member (Rho), and sprout-related EVH1-domain containing (Spred)-1, -2 molecules) and examine the effects on tumor lymphatic investment as well as tumor vascular progression/remodeling has not been examined till date.